

Amie J. Goodin
Curriculum Vitae

1225 CENTER DRIVE, HPNP 3319
GAINESVILLE, FL 32610
Office: (352) 294-8829
amie.goodin@ufl.edu

CURRENT POSITION

Assistant Professor, Tenure Track **2019-Present**
Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida.
Pharmaceutical Health Services Research graduate program track lead.

Affiliations

- Center for Drug Evaluation and Safety (CoDES), Advisory Committee Member
- Consortium for Medical Marijuana Clinical Outcomes Research, Assistant Director Evidence

EDUCATION

PhD **2015**
Martin School of Public Policy and Administration, University of Kentucky, Lexington, KY

Certificate in Informatics **2012**
University of Kentucky, Lexington, KY

Master of Public Policy **2009**
Martin School of Public Policy and Administration, University of Kentucky, Lexington, KY

Bachelor of Science: Biology, Sociology **2007**
University of Kentucky, Lexington, KY

RESEARCH EXPERIENCE

Assistant Scientist, Research Faculty Appointment **2018-2019**
Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida.

Postdoctoral Fellow **2017-2018**
Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida.

Statistics and Research Design Consultant **2014-2020**
Health outcomes research consulting services for several clients in academia and healthcare professional education. *Client references and sample deliverables portfolio available upon request.*

Analyst and Research Assistant **2011-2015**
Institute for Pharmaceutical Outcomes and Policy & Center for the Advancement of Pharmacy Practice, University of Kentucky.

Research Assistant **2008-2011**
Institute for Pharmaceutical Outcomes and Policy, University of Kentucky.

Internship **2008-2010**
Money Follows the Person demonstration grant waiver program, "Kentucky Transitions," Department of Medicaid Services, Frankfort, Kentucky.

PUBLICATIONS

Publications and Presentations Key: * indicates trainee, ** indicates award or special recognition.

1. Unigwe I*, Goodin AJ, Lo-Ciganic WH, Cook RL and H Park. Trajectories of Adherence to Pre-Exposure Prophylaxis (PrEP) and Risks of HIV and Sexually Transmitted Infection. *Clinical Infectious Diseases*. Accepted: December 5, 2023. Forthcoming.

2. Costales B*, Vouri S, Brown JD, Setlow B and **AJ Goodin**. Incident mental health episodes after initiation of gabapentinoids versus dopamine agonists for early-onset idiopathic restless legs syndrome. *Psychiatry Research*. 2023;328(115478):1-9. <https://doi.org/10.1016/j.psychres.2023.115479>
3. **Goodin AJ**, Tran P, McKee S, Sajdeya R, Jyot J, Cook RL, Wang Y and AG Winterstein. Proceedings of the 2023 Cannabis Clinical Outcomes Research Conference. *Medical Cannabis & Cannabinoids*. 2023;6:97-101. <https://doi.org/10.1159/000533943>
4. Varma D, Mualem M, **Goodin AJ**, Gurka KK, Wen TS, Gurka MJ and K Roussos-Ross. Acceptability of a mHealth application to monitor perinatal and postpartum mental health: qualitative study with women and providers. *Journal of Medical Internet Research (JMIR) Formative Research*. 2023;7:e44500. <https://doi.org/10.2196/44500>
5. Hincapie-Castillo JM, Unigwe I*, Vouri SM and **AJ Goodin**. Enhancing active learning of medication errors in the PharmD curriculum through a multi-perspective video-based experience. *Currents in Pharmacy Teaching and Learning*. 2023;15(3):258-265. <https://doi.org/10.1016/j.cptl.2023.03.009>
6. Sajdeya R, Fechtel H, Spandau G, **Goodin AJ**, Brown JD, Jugl S, Smolinski N, Winterstein AG, Cook RL and Y Wang. Protocol of a combined cohort and cross-sectional study of persons receiving medical marijuana in Florida, USA: The Medical Marijuana and Me (M3) Study. *Medical Cannabis & Cannabinoids*. 2023;6(1):46-57. <https://doi.org/10.1159/000530052>
7. Hincapie-Castillo JM and **AJ Goodin**. Using Joinpoint regression for drug utilization research: tutorial and case study of prescription opioid use in the United States. *Pharmacoepidemiology and Drug Safety*. 2023;32(5):509-516. <https://doi.org/10.1002/pds.5606>
8. Park H, Brown C, Wilson DL, Huang PL, Hernandez-Con P, Horne P, **Goodin AJ**, Joseph A, Segal R and RL Cook. Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorders in the United States. *Preventive Medicine Reports*. 2023;32(102138):1-8. <https://doi.org/10.1016/j.pmedr.2023.102138>
9. Hincapie-Castillo, Deravi M*, Vouri S and **AJ Goodin**. Pragmatic model and faculty toolkit for PharmD student engagement in social and administrative pharmacy research. *American Journal of Pharmaceutical Education*. 2023;87(5):100014. <https://doi.org/10.1016/j.ajpe.2023.02.006>
10. Wang X, Zimmermann E, **Goodin AJ**, Brown JD and AG Winterstein. Risk of preterm delivery and small for gestational age among women with inflammatory bowel disease using TNF-alpha inhibitors during pregnancy. *American Journal of Obstetrics & Gynecology*. 2023;228(4):474-476. <https://doi.org/10.1016/j.ajog.2022.12.303>
11. Feld H, Elswick A, **Goodin AJ** and A Fallin-Bennett. Partnering with recovery community centers to build recovery capital by improving access to reproductive health. *Journal of Nursing Scholarship*. 2023;55:692-700. <https://doi.org/10.1111/jnu.12836>
12. Hamad R, Lyman K, Faulkner M, Azar K, **Goodin AJ**, Isasi C, Carmichael H, Knight S, Marcus G, Walraven C, Meissner P, Nair V, O'Brien E, Olgin J, Peyser N, Sylwestrzak G, Williams N, Pletcher M and T Carton. The U.S. COVID-19 County Policy Database: A novel resource to support pandemic-related research. *BMC Public Health*. 2022;22:1882-1894. <https://doi.org/10.1186/s12889-022-14132-6>
13. Smolinski N, Sajdeya R, Cook RL, Wang Y, Winterstein AG and **AJ Goodin**. Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference. *Medical Cannabis and Cannabinoids*. 2022;5:138-141. <https://doi.org/10.1159/000527080>
14. Huang S, Lewis MS, Bao Y, Adekanattu P, Adkins LE, Banerjee S, Bian J, Gellad WF, **Goodin AJ**, Luo Y, Sutton JA, Walunas TL, Wilson DL, Wu Y, Yin P, Oslin DW, Pathak J and WH Lo-Ciganic. Predictive Modeling for Suicide-Related Outcomes and Risk Factors among Patients with Pain Conditions: A Systematic Review. *Journal of Clinical Medicine*. 2022;11(16):4813. <https://doi.org/10.3390/jcm1164813>
15. Costales B*, Vouri SM, Brown JD, Setlow B & **AJ Goodin**. Treatment and utilization patterns of pharmacotherapies for early-onset restless legs syndrome. *Sleep Medicine*. 2022;96:70-78. <https://doi.org/10.1016/j.sleep.2022.05.003>
16. Keshwani S*, Maguire M, **Goodin AJ**, Wilson D, Lo-Ciganic WS & JM Hincapie-Castillo. Buprenorphine use trends following removal of prior authorization policies for the treatment of opioid use disorder in two state Medicaid programs. *JAMA Health Forum*. 2022;3(6):e221757. <https://doi.org/10.1001/jamahealthforum.2022.1757>
17. Park H, Desai R, Lui X, Smith SM, Hincapie-Castillo JM, Henry L, **Goodin AJ**, Gopal S, Pepine CJ & R Mohandas. Medicare bundled payment policy on anemia care, major adverse cardiovascular events, and mortality among adults undergoing hemodialysis. *Clinical Journal of the American Society of Nephrology*. 2022;17(6):851-860. <https://doi.org/10.2215/CJN.14361121>

18. Shen Y*, Hincapie-Castillo JM, Vouri SM, Dewar M, Sumfest J & **AJ Goodin**. Prescription patterns of adjuvant pain medications following an opioid supply restriction law: An interrupted time series analysis. *Medical Care*. 2022;60(6):432-436. <https://doi.org/10.1097/MLR.0000000000001719>
19. **Goodin AJ**, Fallin-Bennett K, Anderson-Hoagland E & A Fallin-Bennett. Tobacco use and mental health disparities in LGB youth. *Public Health Nursing*. 2022;39:659-663. <https://doi.org/10.1111/phn.12997>
20. Oueini R, **Goodin AJ**, Hincapie-Castillo JM and SM Vouri. Co-utilization of opioids and non-benzodiazepine hypnotic drugs in U.S. ambulatory care visits, 2006-2016. *Journal of the American Pharmacists Association*. 2022;62(2):468-474. <https://doi.org/10.1016/j.japh.2021.10.020>
21. Sajdeya R, **Goodin AJ** and Tighe P. Cannabis use assessment and documentation in healthcare: priorities for closing the gap. *Preventive Medicine*. 2021;153:106798. <https://doi.org/10.1016/j.ypmed.2021.106798>
22. Shen Y*, Hincapie-Castillo JM, Vouri SM, Dewar MA, Sumfest JM and **AJ Goodin**. Chronic opioid therapy utilization following an acute pain prescription supply restriction law: an interrupted time series analysis. *Pain Physician*. 2021;24(6):417-424.
23. **Goodin AJ** and JM Hincapie-Castillo. A call to look beyond prescription opioid supply-side restrictions and include health equity when predicting opioid policy effectiveness. *The Lancet Regional Health-Americas*. 2021;3:100075. <https://doi.org/10.1016/j.lana.2021.100075>
24. **Goodin AJ**, Wilson D, Cook R, Wang Y, Brown JD and AG Winterstein. Proceedings and abstracts of the 2021 Cannabis Clinical Outcomes Research Conference. *Medical Cannabis and Cannabinoids*. 2021;4:143-146. <https://doi.org/10.1159/000519037>
25. Delcher C and **AJ Goodin**. Framework for advancing epidemiological criminology research on prescription drug monitoring programs. *American Journal of Criminal Justice*. 2021;46:665-681. <https://doi.org/10.1007/s12103-021-09632-x>
26. Jean-Jacques J, Cook RL, Winterstein AG, **Goodin AJ**, Brown JD, Jugl S and Y Wang. Priorities for medical marijuana research from the perspective of physicians, dispensary owners/staff, and patients: A survey study. *Medical Cannabis & Cannabinoids*. 2021;4:107-113. <https://doi.org/10.1159/000518105>
27. Valdes IL, Possinger MC, Hincapie-Castillo JM, **Goodin AJ**, Dewar MA, Sumfest JM and SM Vouri. Changes in prescribing by provider type following a state prescription opioid restriction law. *Journal of General Internal Medicine*. 2022;37:1838-1844. <https://doi.org/10.1007/s11606-021-06966-4>
28. Keshwani S, Grande I, Maguire M, **Goodin AJ**, Vouri SM and JM Hincapie-Castillo. Trends in Utilization of Prescription Non-Steroidal Anti-Inflammatory Medications Following Florida's Restriction Law of Opioid Prescribing for Acute Pain. *JAMA Network Open*. 2021;4(6):e2113383. <https://doi.org/10.1001/jamanetworkopen.2021.13383>
29. Brown JD, Rivera KJ, Crespo-Hernandez LY, Doenges MR, Auchey I, Pharm T and **AJ Goodin**. Natural and Synthetic Cannabinoids: Pharmacology, Uses, and Adverse Drug Events. *The Journal of Clinical Pharmacology*. 2021;61(S2):S37-S52. <https://doi.org/10.1002/jcph.1871>
30. Oueini R, **Goodin AJ**, Vouri SM, Park H, Lo-Ciganic WH and JM Hincapie-Castillo. Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida's acute pain opioid restriction law. *Journal of Managed Care Pharmacy*. 2021;27(6):779-784. <https://doi.org/10.18553/jmcp.2021.27.6.779>
31. Jugl S, Okpeku A*, Costales B*, Morris EJ, Alipour-Haris G, Hincapie-Castillo J, Stetten NE, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y*, Adkins L, Winterstein AG and **AJ Goodin**. A mapping literature review of medical cannabis clinical outcomes and quality of evidence in approved conditions in the United States from 2016 to 2019. *Medical Cannabis & Cannabinoids*. 2021;4(1): 21-42. <https://doi.org/10.1159/000515069>
32. **Goodin AJ**, Hincapie-Castillo JM, Brown JD and D Roussos-Ross. A Survey Assessment of Clinician Perceptions of Opioid Supply and Monitoring Requirement Policy Changes. *Journal of Opioid Management*. 2021;17(4):337-442.
33. Hincapie-Castillo JM, Easey T, Hernandez C, Maguire M, Usmani SA, Vouri SM and **AJ Goodin**. Changes in quantity of opioids dispensed following Florida's restriction law for acute pain prescriptions. *Pain Medicine*. 2021;22(8):1870-1876. <https://doi.org/10.1093/pm/pnab017>
34. Costales B* and **AJ Goodin**. Outpatients off-label gabapentin utilization for psychiatric indications among United States adults from 2011-2016. *Psychiatric Services*. 2021;72(11):1246-1253. <https://doi.org/10.1176/appi.ps.202000338>
35. **Goodin AJ**, Bae J, Delcher C, Brown JD and D Roussos-Ross. Obstetrician-Gynecologist Perceptions and Utilization of Prescription Drug Monitoring Programs: A Survey Study. *Medicine*. 2021;100:1-6. DOI: <https://doi.org/10.1097/MD.00000000000024268>
36. Sarayani A, Brown JD, **Goodin AJ**, Squires P, Pham P, Cicali B, Henriksen C, Schmidt S and AG Winterstein. A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives- a test case

- for the impact of a known drug-drug interaction. *Epidemiology*. 2021;32(2):268-276. DOI: <https://doi.org/10.1097/EDE.0000000000001302>
37. Shen Y*, Bhagwandass H, Branchcomb T, Grande I, Galvez S, Lessing J, Mollanazar M, Ourhaan N, Oueini R, Sasser M, Valdes I, Jadubans A, Hollman J, Maguire M, Usmani S, Vouri S, Hincapie-Castillo J, Adkins L, and **AJ Goodin**. Chronic Opioid Therapy: A scoping review on evolving clinical and scientific definitions. *The Journal of Pain*. 2021;22(3):246-262. DOI: <https://doi.org/10.1016/j.jpain.2020.09.002>
 38. Usmani SA, Hollman J, **Goodin AJ**, Hincapie-Castillo JM, Adkins LE, Ourhaan N, Oueini R, Bhagwandass H, Easey T and SM Vouri. Effects of Hydrocodone Rescheduling on Opioid Prescribing Outcomes: A Systematic Review. *Journal of the American Pharmacists Association*. 2021;61(2):e20-e44. DOI: <https://doi.org/10.1016/j.japh.2020.09.013>
 39. Bright M, Prieto A, **Goodin AJ**, Watson A and D Roussos-Ross. Increased Tdap and influenza vaccination acquisition among patients participating in group prenatal care: A brief report. *Journal of Primary Prevention*. 2020;41:413-420. DOI: <https://doi.org/10.1007/s10935-020-00606-z>
 40. D Roberson, Roussos-Ross D and **AJ Goodin**. Impact of an on-site perinatal mood disorders clinic in the diagnosis and management of perinatal mood disorders. *Journal of Perinatal Medicine*. 2020;48(8):837-843. DOI: <https://doi.org/10.1515/jpm-2020-0036>
 41. Brown J, Costales B*, Boemmel-Wegmann S, **Goodin AJ**, Segal R and A Winterstein. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. *Journal of Clinical Medicine*. 2020;9(4): 1166. DOI: <https://doi.org/10.3390/jcm9041166>
 42. Padilla M, Roussos-Ross D and **AJ Goodin**. Assessing the Utility of the Healthy Start Screen to Predict an Elevated Edinburgh Postnatal Depression Scale Score. *Journal of Perinatal Medicine*. 2020;48(5): 483-487. DOI: <https://doi.org/10.1515/jpm-2019-0472>
 43. Rhew K, Han N, **Goodin AJ** and JM Oh. Domperidone prescribing patterns in pediatric patients before and after safety warning in South Korea. *International Journal of Clinical Pharmacology and Therapeutics*. 2020;58:687-695. DOI: [10.5414/CP203688](https://doi.org/10.5414/CP203688)
 44. Brown JD, Delcher C, Bae J, Roussos-Ross D and **AJ Goodin**. OB/GYN Perceptions of Prescription Drug Monitoring Programs as a Primary Prevention Tool for Neonatal Abstinence Syndrome. *Research in Social and Administrative Pharmacy*. 2020;16(12):1789-1791. DOI: <https://doi.org/10.1016/j.sapharm.2020.03.010>
 45. Hincapie-Castillo JM, **Goodin AJ**, Possinger MC, Usmani SA and SM Vouri. Changes in Opioid Utilization Following Florida's Restriction Law for Acute Pain Prescriptions. *JAMA Network Open*. 2020;3(2): e200234. DOI: [10.1001/jamanetworkopen.2020.0234](https://doi.org/10.1001/jamanetworkopen.2020.0234)
 46. Shen Y*, Lo-Ciganic WH, Segal R and **AJ Goodin**. Prevalence of Substance Use Disorder and Psychiatric Comorbidity Burden among Pregnant Women with Opioid Use Disorder in a Large Administrative Database, 2009-2014. *Journal of Psychosomatic Obstetrics & Gynecology*. 2020;Feb 17:1-7. DOI: [10.1080/0167482X.2020.1727882](https://doi.org/10.1080/0167482X.2020.1727882)
 47. **Goodin AJ**, Talbert J, Freeman PR, Hahn EJ and A Fallin-Bennett. Appalachian Disparities in Tobacco Cessation Treatment Utilization in Medicaid. *Substance Abuse Treatment, Prevention, and Policy*. 2020;15(5). DOI: <https://doi.org/10.1186/s13011-020-0251-0>
 48. Winterstein A, Bussing R, **Goodin AJ**, Xu D, Keenan M, Turner K, Meyyur V, Duseja R and K Campbell. Development and Validation of an Administrative Claims-Based Measure for All-Cause 30-Day Risk-Standardized Readmissions after Discharge from Inpatient Psychiatric Facilities. *Medical Care*. 2020;58(3): 225-233. DOI: <https://doi.org/10.1097/MLR.0000000000001275>
 49. Cheng Y, **Goodin AJ**, Pahor M, Manini T and JD Brown. Healthcare utilization and physical functioning in older adults in the United States. *Journal of the American Geriatrics Society*. 2020;68: 266-271. DOI: <https://doi.org/10.1111/jgs.16260>
 50. Brown P, RELISH Consortium [Brown JD, **Goodin AJ**], and Y Zhou. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. *Database*. 2019;1-67. DOI: <https://doi.org/10.1093/database/baz085>
 51. Dave C, **Goodin AJ**, Zhu Y, Winterstein A, Wang X, Alrwisan A and A Hartzema. Prevalence of Maternal Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015. *Pharmacotherapy*. 2019;39(10): 1005-1011. DOI: <https://doi.org/10.1002/phar.2315>
 52. **Goodin AJ**, Elswick A, and A Fallin-Bennett. Mental Health Disparities and High-Risk Alcohol Use among non-Heterosexual High School Students. *Perspectives in Psychiatric Care*. 2019;55:570-575. DOI: <https://doi.org/10.1111/ppc.12394>

53. **Goodin AJ**, Brown JD, Delcher C, Freeman PR, Talbert J, Henry S and D Roussos-Ross. Perception of Prescription Drug Monitoring Program Effectiveness in Primary Care. *Research in Social and Administrative Pharmacy*. 2020;16(9):1306-1308. DOI: <https://doi.org/10.1016/j.sapharm.2019.03.012>
54. Fallin-Bennett A, Rademacher K, Dye H, Elswick A, Ashford K and **AJ Goodin**. Perinatal Navigator Approach to Smoking Cessation for Women with Prevalent Opioid Dependence. *Western Journal of Nursing Research*. 2019;89(3): 219-225. DOI: <https://doi.org/10.1177/0193945918825381>
55. Brown JD and **AJ Goodin**. The Prevalence of Drivers Under the Influence of Medical Cannabis Must be Considered within Proper Context. *Research in Social and Administrative Pharmacy*. 2019;15(11):1372-1372. DOI: <https://doi.org/10.1016/j.sapharm.2019.01.015>
56. Fallin-Bennett A and **AJ Goodin**. Substance Use and School Characteristics in Lesbian, Gay, Bisexual, and Heterosexual High School Students. *Journal of School Health*. 2019;89(3):219-225. DOI: <https://doi.org/10.1111/josh.12731>
57. Brown J, **Goodin AJ** and G Lip. Bleeding Risk Scores in Patients Receiving Anticoagulation for Venous Thromboembolism: Simplicity and Practicality Matter. *Journal of Thrombosis and Haemostasis*. 2018;16:2537-2539. DOI: <https://doi.org/10.1111/jth.14301>
58. **AJ Goodin**. Opioid Epidemic: We Cannot Treat the Dead. *American Journal of Public Health*. 2018;108(10): 1286-1288. DOI: 10.2105/AJPH.2018.304658
59. Delcher C, Wang Y, **Goodin AJ**, Freeman PR and G Reisfield. Rapid expansion of the opioid “ecosystem”: national implications for prescriber-pharmacist communication. *American Journal of Preventive Medicine*. 2018;55(5): 656-661. DOI: <https://doi.org/10.1016/j.amepre.2018.05.003>
60. J Brown and **AJ Goodin**. Age Restrictions for Firearm Purchases to Reduce Mass Casualty Shootings in Schools and Other Venues. *American Journal of Public Health*. 2018;108(10):1385-1387. DOI: 10.2105/AJPH.2018.304584
61. Chen M, **Goodin AJ**, Xiao H, Han Q, Raissi D and J Brown. Hospitalization Metrics Associated with Hospital-level Variation in Inferior Vena Cava Filter Utilization for Patients with Venous Thromboembolism in the United States: Implications for Quality of Care. *Vascular Medicine*. 2018;23(4):365-371. DOI: <https://doi.org/10.1177/1358863X18768685>
62. **Goodin AJ**, Han Q, Raissi D and J Brown. A Review of Interventions to Increase Vena Cava Filter Retrieval Rates. *Annals of Vascular Surgery*. 2018;51:284-297. DOI: 10.1016/j.avsg.2018.02.010
63. **Goodin AJ**, Chen M, Raissi D, Han Q, Xiao H and J Brown. Hospital Characteristics Predictive of Inferior Vena Cava Filter Usage in Venous Thromboembolism Patients: A Study from the 2013-2014 Nationwide Readmissions Database. *Medicine*. 2018;97(12):e0149. DOI: 10.1097/MD.00000000000010149
64. Brown J, **Goodin AJ**, Lip G and V Adams. Risk stratification for bleeding complications in patients with venous thromboembolism: Application of the HAS-BLED bleeding score during the first six months of anticoagulant treatment. *Journal of the American Heart Association*. 2018;7(6):e007901. DOI: <https://doi.org/10.1161/JAHA.117.007901>
65. **Goodin AJ**, Fallin-Bennett A, Green TC and PR Freeman. Pharmacists’ Role in Harm Reduction: A Survey Assessment of Kentucky Community Pharmacists’ Willingness to Participate in Syringe/Needle Exchange. *Harm Reduction Journal* 2018;15(4):1-9. DOI: [10.1186/s12954-018-0211-4](https://doi.org/10.1186/s12954-018-0211-4)
66. Brown JB, **Goodin AJ**, Talbert J. Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. *Journal of Rural Health* 2018;34(1):6-13. DOI: 10.1111/jrh.12251
HCUP Outstanding Article of the Year Award from AHRQ and Academy Health: Honorable Mention
67. Moga DC, Wu Q, Doshi P and **AJ Goodin**. An Investigation of Factors Predicting the Type of Bladder Antimuscarinics Initiated in Medicare Nursing Homes Residents. *BMC Geriatrics* 2017;17(1): 295. DOI: 10.1186/s12888-017-0690-2
68. **Goodin AJ**, Delcher C, Valenzuela C, Wang X, Zhu Y, Roussos-Ross D and J Brown. The Power and Pitfalls of Big Data Research in Obstetrics & Gynecology: A Consumer’s Guide. *Obstetrical & Gynecological Survey* 2017;72(11): 669-682. DOI: 10.1097/OGX.0000000000000504 **Certified for CME Credit by the American Medical Association**
69. Freeman TR, **Goodin AJ**, Troske S, Strahl A, Fallin A, and TC Green. Pharmacists’ Role in Opioid Overdose: Kentucky Pharmacists’ Willingness to Participate in Naloxone Dispensing. *Journal of the American Pharmacists Association* 2017;57(2S): 28-33. DOI: <http://dx.doi.org/10.1016/j.japh.2016.12.064>

70. Triplett K, **Goodin AJ**, Delcher C, Brown J and D Roussos-Ross. Opioid Drug Exposures and Health Care Utilization Measures Associated with Neonatal Abstinence Syndrome in Florida, 2011-2015. *Journal of Gynecology & Obstetrics* 2017;1(4): 018.
71. Wixson S, Blumenschein K, **Goodin AJ**, Talbert J, and PR Freeman. Prescription Drug Monitoring Program Utilization in Kentucky Community Pharmacies. *Pharmacy Practice* 2015;13(2): 540-545. PMID: PMC4482842
72. Fallin A, **Goodin AJ**, Lee YO, and K Bennett. Smoking Cessation Awareness and Utilization among Lesbian, Gay, Bisexual, and Transgender Adults: An Analysis of the 2009-2010 National Adult Tobacco Survey. *Nicotine & Tobacco Research* 2015;18(4): 496-500. DOI: 10.1093/ntr/ntv103
73. Hickson R, Perin N, Talbert J, Thornbury W, and **AJ Goodin**. Online Medical Care: The Current State of eVisits in Primary Care Delivery. *Telemedicine and e-Health* 2015;21(2): 1-7. DOI: 10.1089/tmj.2014.0022
74. Fallin A, **Goodin AJ**, and B King. Menthol Cigarette Smoking among Lesbian, Gay, Bisexual, and Transgender Adults in the U.S. *American Journal of Preventive Medicine* 2015;48(1):93-97. DOI: <http://dx.doi.org/10.1016/j.amepre.2014.07.044>
75. Fallin A, **Goodin AJ**, Lee YO, and K Bennett. Smoking Characteristics Among Lesbian, Gay, and Bisexual Adults. *Preventive Medicine* 2015;74:123-130. DOI: 10.1016/j.ypmed.2014.11.026
76. Fallin A, **Goodin AJ**, Rayens MK, Morris S, and EJ Hahn. Smoke-Free Policy Implementation: Theoretical and Practical Considerations. *Policy, Politics, & Nursing Practice* 2014;15(3-4):81-92. DOI: <https://doi.org/10.1177/1527154414562301>
77. Wixson S, Freeman PR, Blumenschein K, Talbert J, **Goodin AJ**, Higgins GE, and GF Vito. Law Enforcement Perceptions of a Prescription Drug Monitoring Program. *International Journal of Police Science & Management* 2014;16(4): 288-296. DOI: <https://doi.org/10.1350/ijps.2014.16.4.347>
78. Monson K, Freeman PR, **Goodin AJ**, Talbert J, and K Blumenschein. Kentucky Pharmacist Opinions of the Potential Reclassification of Pseudoephedrine as a Legend Drug. *Journal of the American Pharmacists Association* 2014;54(4): 391-405. DOI: <http://dx.doi.org/10.1331/JAPhA.2014.13177>
79. **Goodin AJ** Blumenschein K, Freeman P, and J Talbert. Consumer/Patient Encounters with Prescription Drug Monitoring Programs: Evidence from a Medicaid Population. *Pain Physician* 2012;15(3S): 169-175. PMID: PMC3545447

Book Chapters

1. Clark A*, Talbert J and **AJ Goodin**. Controlled Substance and Pharmaceutical Policy. In: *Kentucky Government, Politics, and Public Policy, 2nd Edition*. Clinger J, ed. University Press of Kentucky. Lexington, KY. Accepted: November 2022. Forthcoming.
2. **AJ Goodin** and N Pauly. Chapter 49: Health Policy and Pharmacy. In: *Remington- The Science and Practice of Pharmacy, Section 10: Pharmaceutical Outcomes and Policy, 23rd Edition*, A Adejare, editor. Elsevier, Academic Press, Cambridge, MA. October 2020.
3. **AJ Goodin** and K Blumenschein. Chapter 8: Measurement. In: *Principles of Research Design and Drug Literature Evaluation, Second Edition*, Aparasu R and J Bentley, eds. McGraw-Hill Global Education Holdings, LLC. New York, NY. October 2019.
4. Blumenschein K and **AJ Goodin**. Chapter 8: Measurement and Descriptive Analysis. In: *Principles of Research Design and Drug Literature Evaluation*, Aparasu R and J Bentley, eds. Jones & Bartlett Learning, LLC. Burlington, MA. March, 2014.
5. **Goodin AJ** and J Talbert. Politics of Kentucky Pharmacy Regulation. In: *Kentucky Government, Politics, and Public Policy*, Clinger J and M Hail, eds. University Press of Kentucky. Lexington, KY. November, 2013.

Other Publications and Registered Protocols

1. Recurring critical commentary series in *Medical Cannabis & Cannabinoids*: **Goodin AJ**, Winterstein AG, Cook R, Wang Y and JD Brown. Introducing Commentary Series: "Evidence in Context." *Medical Cannabis & Cannabinoids*. 2021;4(1):61-62. <https://doi.org/10.1159/000512684>
2. Brown JD and **AJ Goodin**. High risk of bias in medical cannabis and cannabinoid clinical trials dictates the need for cautious interpretation. *Medical Cannabis & Cannabinoids*. 2021;4(1):63-66. <https://doi.org/10.1159/000514732>
3. Sajdeya R, Brown JD and **AJ Goodin**. Perinatal Cannabis Exposures and Autism Spectrum Disorders. *Medical Cannabis & Cannabinoids*. 2021;4(1):67-71. <https://doi.org/10.1159/000515871>

4. Jugl S, Sajdeya R, Morris E, **Goodin AJ** and JD Brown. Much Ado about Dosing: The needs and challenges of defining a standardized cannabis unit. *Medical Cannabis & Cannabinoids*. 2021;4(2):121-124. <https://doi.org/10.1159/000517154>
5. Brown JD and **AJ Goodin**. Will cannabis or cannabinoids protect from SARS-CoV-2 infection or treat COVID-19? *Medical Cannabis & Cannabinoids*. 2022;5(1):1-4. <https://doi.org/10.1159/000522472>
6. Sajdeya R, Jugl S, Cook RL, Brown JD and **AJ Goodin**. Clinical considerations for cannabis use and cardiovascular health. *Medical Cannabis & Cannabinoids*. 2022;5(1):120-127. <https://doi.org/10.1159/000526731>
7. Sagen J, Konin J, Paikoff S, Ford J, Newman D, Jyot J and **AJ Goodin**. Abstracts of the 2022 Cannabis Clinical Outcomes Research Conference (CCORC), on behalf of the Scientific Program Committee. *Medical Cannabis & Cannabinoids*. 2022;5:142-158. <https://doi.org/10.1159/000527081>
8. Costales B*, Babalonis S, Brown JD and **AJ Goodin**. Cannabis effects on driving performance: clinical considerations. *Medical Cannabis & Cannabinoids*. 2023;6:8-14. <https://doi.org/10.1159/000528714>
9. Jugl S*, **Goodin AJ** and JD Brown. Climbing the evidence pyramid: dosing considerations for medical cannabis in the management of chronic pain. *Medical Cannabis & Cannabinoids*. 2023;6:41-45. <https://doi.org/10.1159/000530251>
10. **AJ Goodin**, S Jugl*, HY Lin*, HK Chen*, T Zhang*, W Huang*, A Winterstein, Y Wang, Adkins and S Guo. The Medical Use of Cannabis on Post-Traumatic Stress Disorder Treatment Outcomes: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023411930](https://doi.org/10.1159/000530251)
11. P Kulkarni*, HK Chen*, D Guan*, P Kotecha*, W Huang*, S Niu*, K Smith*, N Gaizo*, T Zhang*, Y Wang*, L Adkins, A Winterstein, S Guo, Y Wang and **AJ Goodin**. The Medical Use of Cannabis as Treatment for Pain: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023412045](https://doi.org/10.1159/000530251)
12. S Niu*, T Kurzbach*, M Scott*, P Kulkarni*, L Adkins, A Winterstein, S Guo, Y Wang and **AJ Goodin**. The Medical Use of Cannabis as Treatment for Epilepsy and Related Seizure Disorders: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023412008](https://doi.org/10.1159/000530251)
13. S Jugl*, HK Chen*, SH Chang*, Y Wang*, T Kurzbach*, L Adkins, A Winterstein, S Guo, Y Wang and **AJ Goodin**. The Medical Use of Cannabis on Inflammatory Bowel Disease Treatment Outcomes: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023411910](https://doi.org/10.1159/000530251)
14. T Kurzbach*, P Poelzing*, S Niu*, D Guan*, L Adkins, A Winterstein, S Guo, Y Wang and **AJ Goodin**. The Medical Use of Cannabis on Anorexia Treatment Outcomes: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023411875](https://doi.org/10.1159/000530251)
15. P Kotecha*, W Huang*, J Wiener*, S Jugl*, MI Chatila*, C Naranjo*, S Guo, A Winterstein, Y Wang, L Adkins, and **AJ Goodin**. The Medical Use of Cannabis on Anxiety Treatment Outcomes: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023411999](https://doi.org/10.1159/000530251)
16. P Kotecha*, SH Chang*, HY Lin*, P Poelzing*, S Guo, A Winterstein, Y Wang, L Adkins, and **AJ Goodin**. The Medical Use of Cannabis as Treatment for Nausea: A Systematic Review and Meta-Analysis. PROSPERO Registration and Citation Link: [CRD42023412005](https://doi.org/10.1159/000530251)

[Google Scholar Bibliography](#)

[ResearchGate Profile](#)

[NCBI Bibliography](#)

[ORCID](#)

GRANTS & RESEARCH SUPPORT

Current and Pending Grants and Support

International Society of Pharmacoepidemiology (ISPE) Funded Manuscripts. December 2024-December 2025

Project: **Curriculum Assessment of Pharmacoepidemiology Training Programs.**

PI: AJ Goodin. Award Amount: \$4,740.

Role: Principal Investigator.

Florida Department of Health, with Health Resources and Services Administration (HRSA). July 2023-June 2024

Project: **Reducing Maternal Morbidity and Mortality, Phase 3: Incorporating Antepartum Care and Problematic Substance Use Assessment.**

MPIs: D Roussos-Ross and D Varma. Award Amount: \$620,504.

Role: co-Investigator (15%).

University of Florida Research Opportunity Seed Fund. June 2022-May 2024
Project: **Assessing Prevalence, Maternal Perceptions, and Fetal Development Outcomes of Perinatal Marijuana Use.**
MPIs: D Roussos-Ross, AJ Goodin, D Varma, B Goldberger. Award Amount: \$90,000.
Role: Multi-Principal Investigator.

State of Florida. July 2019-June 2024
Project: **The Consortium for Medical Marijuana Clinical Outcomes Research.**
PI: A Winterstein. Award Amount: \$6,000,000 (annual state appropriation of \$1.5M).
Role: co-Investigator (20% Year 1; 35% Years 2-2.5; 50% Year 2.5-3, 30% Years 3).
Sub-Project: **Evidence Core**
Award Amount: \$233,692
Role: Sub-Project Principal Investigator (30% Year 4).

Completed Grants & Indexed Technical Reports

United States Food and Drug Administration (FDA). January 2023-August 2023
Task Order: #75F40123F19008
Project: **Medical Literature and Data on Cannabis Use.**
PI: AJ Goodin. Award Amount: \$328,281.
Role: Principal Investigator (75%).

Florida Department of Health. July 2022-June 2023
Project: **Reducing Maternal Morbidity and Mortality: phase 2.**
PI: D Roussos-Ross. Award Amount: \$322,438.
Role: co-Investigator (12%).

Voices of Hope, Inc. January 2022-December 2022
Project: **Program Evaluation and Analytic Support Services for a Substance Use Disorders Recovery Community Center.**
PI: AJ Goodin. Award Amount: \$47,625.
Role: Principal Investigator (10%).

National Institute of Mental Health (NIMH). August 2021-August 2022
Project: **Applying big data to improve mental health outcomes with restless legs syndrome treatment.**
PI: Brianna Costales. Mental Health Research Dissertation Grant to Enhance Workforce Diversity (NIH R36). Award Amount: \$36,797.
Role: Primary Mentor.

Florida Department of Health. July 2021-June 2022
Project: **Reducing Maternal Morbidity and Mortality in the COVID-19 Era.**
PI: D Roussos-Ross. Award Amount: \$192,500.
Role: co-Investigator (10%).

Rx Abuse Leadership Initiative (RALI). April 2021-March 2022
Project: **Opioid Disposal in Post-Surgical Patients Using an At-Home Drug Disposal Delivery.**
MPIs: SM Vouri & AJ Goodin. Award Amount: \$3,000.
Role: Multi-Principal Investigator.

Voices of Hope, Inc. July 2019-December 2021
Project: **Program Evaluation and Analytic Support Services for a Substance Use Disorders Recovery Community Center.**
PI: AJ Goodin. Award Amount: \$40,454.
Role: Principal Investigator (5%).

Bill and Melinda Gates Foundation. March 2018-December 2021

Project: **Application of Physiologically-based Pharmacokinetic Models to Inform Dosing Recommendations for Hormonal Contraceptives co-Administered with Other Medications.**

PI: S Schmidt. Award Amount: \$1,499,992.

Sub-project: *Drug-Drug Interactions with Hormonal Contraceptive Agents- Prevalence and Real-World Effects on Unwanted Pregnancy and Venous Thromboembolism.*

Role: co-Investigator, sub-project (50% year 1).

UF Clinical and Translational Sciences Institute (CTSI) Precision Health Initiative Pilot Funding. July 2020-July 2021

Project: **Estimating Patterns of Geographic Variation and Social Determinants of Health that Impact Breastfeeding Outcomes Using Natural Language Processing and Electronic Health Records.**

PI: D Lemas. Award Amount: \$49,941.

Role: co-Investigator.

American Association of Colleges of Pharmacy (AACP).

March 2020-February 2021

Project: **Leveraging Social Media Data for Evaluation of Drug Use Trends after Opioid Policies.**

PI: J Hincapie-Castillo. Award Amount: \$10,000.

Role: co-Investigator.

Consortium for Medical Marijuana Clinical Outcomes Research.

December 2019-December 2020

Project: **Characterizing Community and Physician-Level Factors Associated with Medical Marijuana Prescriber Registration and Patient Access.**

PI: J Brown and AJ Goodin. Award Amount: \$38,191.

Role: co-Principal Investigator (10%).

UF PROSPER Development of Innovative Teaching Approaches Award.

June 2019-June 2020

Project: **Enhancing Active Learning of a Root Cause Analysis on a Medication Error in the *Patient Safety and Quality in Pharmacy Course.***

Co-PIs: S Vouri and AJ Goodin. Award Amount: \$15,000

Role: co-Principal Investigator.

UF Health Shands Endowment Fund.

January 2019-June 2020

Project: **All-Cause Readmission Measures on Inpatient Psychiatry Facilities.**

PI: AJ Goodin. Award Amount: \$31,755.

Role: Principal Investigator.

Creative Educational Concepts, Inc.

April 2019-April 2020

Project: **Evaluating Learning Outcomes in Continuing Pharmacy and Medical Education.**

PI: AJ Goodin. Award Amount: \$12,000

Role: Principal Investigator (5%).

Centers for Medicare and Medicaid Services.

September 2014-February 2019

Project: **Inpatient Psychiatric Facility Outcome and Process Measure Development and Maintenance.**

Subcontract to UF/UF Health with Health Services Advisory Group. HHSM-500-2013-13007I [HHSM-500-T0004].

PI: A Winterstein. Award Amount: \$2,006,320 (UF portion).

Role: Project Coordinator (50%).

Foundation for a Healthy Kentucky.

December 2016-June 2017

Project: **Tobacco Treatment Access and Utilization in Kentucky's Medicaid Population Over Time.**

Rapid Response Grant. PI: A Fallin-Bennett. Award Amount: \$10,000.

Role: co-Investigator.

Bureau of Justice Assistance.

July 2011-January 2015

Project: **Kentucky House Bill 1 Impact Evaluation**, Evaluating the Impact of Mandatory Prescription Drug Monitoring Program Query on Controlled Substance Prescribing and Opioid-Related Outcomes.

Federal Comprehensive Opioid Abuse Program (COAP), Harold Rogers Grant # 2011-PM-BX-0007. PI: PR Freeman. Award Amount: \$400,000. [Technical report link.](#)

Role: co-Investigator.

National Institute of Justice.

July 2012-September 2015

Project: **Optimizing Prescription Drug Monitoring Programs to Support Law Enforcement Activities.**

Grant # 2012-R2-CX-0007. PI: PR Freeman. Award Amount: \$363,226. National Criminal Justice Reference Service report #249186; [Technical report link.](#)

Role: Data Analyst.

Scored Grants, Not Funded

Agency for Healthcare Research and Quality (AHRQ).

Project: **Evaluating unanticipated consequences of opioid prescribing restriction laws to inform policy implementation strategies and improve care quality in Medicaid.** Small Research Grant Program (R03). Submitted July 2021. Score: 20th percentile, not funded.

Role: contact Multi-Principal Investigator (10%) with JM Hincapie-Castillo.

National Institute on Drug Abuse (NIH-NIDA).

Project: **Medication use trajectories for opioid use disorders among pregnant women and resulting neonatal outcomes.** NIH Mentored Research Scientist Development Award (K01). Submitted July 2021. Score: 14th percentile, not funded.

Role: Principal Investigator (75%).

Project: **Real-world utilization of prescription opioids by pregnant patients: prescribing patterns, outcomes, and the impact of a prenatal risk assessment screening.** Submitted to NIH-NIDA, Pathway to Independence Career Development Award: K99/R00, submitted October 2018. Scored, not funded.

Role: Principal Investigator.

Project: **The Impact of the Affordable Care Act on Contraception Choices and Pregnancies in Medicaid and Commercially Insured Patients.** Robert Wood Johnson Foundation, Culture of Health Evidence 4 Action Series, LOI accepted November 2018 (scored in top 10%), full proposal submitted December 2018. Co-PIs: A Goodin and M Maldonado-Molina. Not funded.

Role: co-Principal Investigator.

TEACHING EXPERIENCE

Instructor

2018-Present

College of Pharmacy, University of Florida.

- **Course co-Coordinator**, with S Vouri | R Reise: Patient Safety & Quality in Pharmacy, mandatory course in 3rd year of PharmD training. Fall 2019-2023 (annually). 3 credit hours, ~250 students.
- Pharmacy & Population Health, mandatory course in 1st year of PharmD training. Fall 2019-2023 (annually). Health Policy Module. 2 credit hours, ~250 students.
- Patient Care VII: Brain and Behavior, mandatory course in 3rd year of PharmD training. Spring 2019-2024 (annually). Lecturer for: quality assessment, case control study designs, and patient-reported outcomes for neuropsychiatric disorders. 6 credit hours, ~200 students.

Instructor

2018-Present

Graduate School, University of Florida.

- Introduction to Graduate Studies, graduate-level seminar course. Fall 2020-2023 (annually). "How to Present at Journal Club" module. 3 credit hours.
- Introduction to Pharmaceutical Outcomes and Policy, graduate-level seminar and discussion course. Spring 2019-2024 (annually). "Introduction to Health Services Research and Health Policy" modules and "Publishing" module. 3 credit hours.
- Measurement in Pharmaceutical Outcomes and Policy Research, graduate-level seminar and discussion course. Fall 2018, Spring 2020, Spring 2021, Fall 2022, Co-Instructor with A Winterstein. Spring 2024, Co-Instructor with S Smith. 3 credit hours.

Academic Appointment, Instructor

2012-2014

Gatton College of Business and Economics, University of Kentucky.

- Economic and Business Statistics, an introduction to econometrics and regression models. Spring 2014. Primary Instructor, 3 credit hours, 41 students.
- Contemporary Economic Issues, a writing and discussion-intensive course introducing a variety of economic principles. Fall 2012, Spring 2013. Primary Instructor and Course Co-Developer with G Hoyt, 3 credit hours, 33 and 53 students.
- Introduction to Microeconomics, an algebra-based introduction to microeconomic theory. Spring 2012. Primary Instructor, 3 credit hours, 54 students.

Teaching Assistant

2007-2008

College of Pharmacy, PharmD Program, University of Kentucky.

- Pharmaceutical Policy and Public Health, Course Coordinator Dr. Douglas Steinke.
- Pharmacy Practice Management, Course Coordinator Dr. David Nau.
- Legal, Ethical, and Access Issues in Pharmacy, Course Coordinator Dr. Joseph Fink.

PUBLISHED ABSTRACTS, PEER-REVIEWED PRESENTATIONS, & INVITED PRESENTATIONS

Invited Presentations

The MOMitor™ App: A digital screening and intervention tool for improving postpartum care quality and outcomes, with K Roussos-Ross, D Varma, T Wen. Grand Rounds, Department of OB-GYN, College of Medicine, University of Florida. January 19, 2024.

Lessons Learned from the Medical Cannabis Evidence Review. “DARE (Data, Analytics, Research, and Epidemiology)” Seminar Series hosted by the FDA Sentinel Operations Center at Harvard Pilgrim. Virtual Presentation. October 4, 2023.

Curriculum in Pharmacoepidemiology Training and Alignment with Updated Core Competencies: State of the Field and Educational Needs Assessment. Symposia, Lead Speaker, with the ISPE Core Competencies workgroup. The 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). Halifax, Canada. August 25, 2023.

Opioid Prescribing and Opioid Use Disorder Treatment in the United States. Session Chair and Discussant. Academy Health 2023 Annual Research Meeting. Seattle, Washington. June 25, 2023.

Legal epidemiology applications for measuring substance use and substance use disorder treatment. University of Kentucky, Local Neuroscientists Interested in Drug Abuse Research (“Local NIDA”). Lexington, Kentucky [Virtual]. September 29, 2022.

Policy effects on substance access and use: applying a legal epidemiology framework. University of Kentucky, Substance Use Priority Research Area (SUPRA) “Welcome Home” Seminar Series. Lexington, Kentucky [Virtual]. September 2, 2022.

Shaping the future of pharmacoepidemiology. Workshop, with Vicki Osborne and on behalf of the ISPE core competencies in pharmacoepidemiology workgroup. The 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). Copenhagen, Denmark. August 28, 2022.

Utilizing social media to advance your career as a pharmacoepidemiologist. Workshop, with JM Hincapie-Castillo and M Tadrous. International Society of Pharmacoepidemiology (ISPE). Virtual. June 9, 2022.

A model for successful faculty-student research collaboration: You Can’t Go It Alone. Special Session, with Juan Hincapie-Castillo and Scott Vouri. The 2021 American Association of Colleges of Pharmacy (AACP) Annual Meeting. Virtual due to COVID. July 22, 2021.

Marketplace Insurance Coverage: Key Issues and Comparisons with Medicaid. Session Chair and Discussant. Academy Health 2021 Annual Research Meeting. Virtual due to COVID. June 15, 2021.

Methods to evaluate the effects of policy changes during the opioid crisis. Symposia, with Mina Tadrous, Gerald Dal

Pan, and Juan Hincapie-Castillo. The 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) All-Access. Virtual due to COVID. November 12, 2020.

Evaluating health and pharmaceutical policy affecting populations with disparate access to care: can we measure what we can't 'see'? University of Kentucky. May 22, 2019. Lexington, Kentucky.

International and National Presentations, selected

Publications and Presentations Key: * indicates trainee, ** indicates award or special recognition.

1. Roussos-Ross D, Wen T, Jiao T, Varma DS and **AJ Goodin**. Utilizing ecological momentary assessment in the evaluation of patients with hypertensive disorders of pregnancy. [Poster] The Society for Maternal-Fetal Medicine (SMFM)'s 2024 Pregnancy Meeting. National Harbor, MD. February 14, 2024.
Published in: *American Journal of Obstetrics & Gynecology*. Forthcoming.
2. Roussos-Ross D, Wen T, Varma DS and **AJ Goodin**. Analyzing the utility of ecological momentary assessment in the evaluation of postpartum depression. [Poster] The Society for Maternal-Fetal Medicine (SMFM)'s 2024 Pregnancy Meeting. National Harbor, MD. February 14, 2024.
Published in: *American Journal of Obstetrics & Gynecology*. Forthcoming.
3. Roussos-Ross D, Varma DS, Dhillon K, Jennings-Coulbaly A, Kaleem S, Wen T and **AJ Goodin**. Postpartum Care Quality: Real-Time Postpartum Symptom Monitoring through Gator MOMitor.™ [Podium] The South Atlantic Association of Obstetricians and Gynecologists Annual Meeting. Sea Island, Georgia. January 23, 2024.
4. **Goodin AJ**, Maguire M and A Fallin-Bennett. Tobacco cessation treatment in Kentucky Medicaid following coverage policy expansion. [Poster] The 2023 Academy Health Annual Research Meeting. Seattle, WA. June 25, 2023.
5. **Goodin AJ**, Varma DS, Dhillon K, Jennings-Coulbaly A, Kaleem S, Wen T and D Roussos-Ross. Smartphone application to improve postpartum care quality: preliminary evaluation. [Poster] The 2023 Academy Health Annual Research Meeting. Seattle, WA. June 25, 2023.
6. Kaleem S, Roussos-Ross K, Dhillon K, Goldberger B, Varma DS, Abu-Rustum R, Ramirez-Zamora A and **AJ Goodin AJ**. Survey assessment of cannabis use in an obstetrics and gynecology clinic. [Poster] The American Society of Addiction Medicine (ASAM) 54th Annual Conference. Washington, DC. April 2023.
Published in: *Journal of Addiction Medicine*, forthcoming.
7. Varma D, **Goodin AJ**, Dhillon K, Kaleem S, Wen T, Jennings-Coulbaly A and K Roussos-Ross. Postpartum mood assessment and intervention using a smartphone-based application. [Poster] The American College of Obstetricians and Gynecology (ACOG) Annual Clinical and Scientific Meeting. Baltimore, MD, May 2023.
Published in: *Obstetrics & Gynecology*. 141(5):65S-66S.
8. **Goodin AJ**, Varma D, Dhillon K, Jennings-Coulbaly A, Wen T and K Roussos-Ross. Real-time assessment of symptoms for postpartum care via a smartphone application: Pilot Evaluation. [Poster] The American College of Obstetricians and Gynecology (ACOG) Annual Clinical and Scientific Meeting. Baltimore, MD, May 2023.
Published in: *Obstetrics & Gynecology*. 141(5):65S-66S.
9. Huang S, Lewis M, Bao Y, Bian J, Gellad WF, Wu Y, Pathak J, Oslin D, Adkins LE, Yin P, Sutton JA, **Goodin AJ**, Wang F, Banerjee S, Adekanattu P, Wilson DL and WH Lo-Ciganic. Predictive Modeling for Suicide-Related Outcomes and Risk Factors Among Patients with Pain Conditions: A Systematic Review. [Poster] The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. Washington, DC, May 2022.
Published in: *Value in Health*. 2022;25(7):S327.
10. Costales B*, Setlow B, Vouri SM, Brown JD and **AJ Goodin**. Initiation of pharmacotherapies for newly diagnosed early-onset idiopathic restless legs syndrome from 2012-2019. [Poster] The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. Washington, DC, May 2022.
Published in: *Value in Health*. 2022;25(7):S329.
11. Shen Y* and **AJ Goodin**. The effect of standing orders on number of naloxone prescriptions reimbursed by Medicaid in California. [Poster] The 2021 Addiction Health Services Research Conference. Virtual, October 2021.
Published in: *Addiction Science and Clinical Practice*.
12. Keshwani S*, **Goodin AJ**, Lo-Ciganic WH and JM Hincapie-Castillo. Buprenorphine use trends following prior authorization policy change for opioid use disorder treatment in state Medicaid programs, from 2013-2020. [Poster] The 2021 Addiction Health Services Research Conference. Virtual, October 2021.
Published in: *Addiction Science and Clinical Practice*.

13. Okpeku A*, Park H and **AJ Goodin**. Hospital 30-day all-cause readmission risk among people living with HIV with mental health condition and substance use disorder status. [Poster] The 2021 Addiction Health Services Research Conference. Virtual, October 2021.
Published in: *Addiction Science and Clinical Practice*.
14. Sajdeya R, Jugl S, **Goodin AJ** and RL Cook. Free-text searching algorithms to identify patients using cannabis in electronic health records: A rapid literature review. [Poster] The 2021 Addiction Health Services Research Conference. Virtual, October 2021.
Published in: *Addiction Science and Clinical Practice*.
15. Hincapie-Castillo JM, **Goodin AJ**, Allen J, Grundman O and T Cavanaugh. A spatiotemporal evaluation of community pharmacy practice experience site placement within diverse patient communities (2016-2020). [Poster] American Association for Colleges of Pharmacy 2020 Annual Meeting. Virtual, July 2021.
16. Jugl S, Sajdeya R, Cook RL, Brown JD, Winterstein AG and **AJ Goodin**. Legalization of “smokable” medical marijuana was associated with significantly increased THC use per certified patient in the Florida medical marijuana program: An interrupted time series analysis. [Poster] Research Society for Marijuana 5th Annual Scientific Meeting. July 2021. ****Selected for “Flash Talk” Presentation****
Published in: *Cannabis*. 2022;5(1):109-110.
17. Oueini R*, Hincapie-Castillo JM, **Goodin AJ** and S Vouri. Co-utilization of opioids and non-benzodiazepine sedative hypnotics in U.S. ambulatory care visits, 2006-2016. [Poster] International Society of Pharmacoepidemiology 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 2021.
Published in: *Pharmacoepidemiology & Drug Safety*. 2021;30(S1):100-101.
18. Costales B*, Matthews R*, Brown J and **AJ Goodin**. A pharmacovigilance analysis of restless leg syndrome treatments and suicidality. [Poster] International Society of Pharmacoepidemiology 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 2021.
Published in: *Pharmacoepidemiology & Drug Safety*. 2021;30(S1):124-125.
19. Ourhaan N*, Bhagwandass H*, **Goodin AJ** and JM Hincapie-Castillo. Trends in Utilization of amphetamine-containing medications following state level restriction laws for acute pain opioid prescriptions. [Poster] International Society of Pharmacoeconomics and Outcomes Research 2021 Annual Meeting. Virtual. ****Top 5 Student Abstract Award****
Published in: *Value in Health*. 2021;24:S89-S90.
20. Staret J*, **Goodin AJ**, Bhagwandass H* and JM Hincapie-Castillo. Changes in Schedule II opioid prescriptions dispensed by Medicaid following acute pain opioid restriction laws. International Society for Pharmacoeconomics Outcomes Research 2021 Annual Meeting. Virtual.
Published in: *Value in Health*. 2021;24:S149.
21. Easey T*, Vouri SM, **Goodin AJ** and Hincapie-Castillo JM. Impact of state laws restricting opioid prescriptions for acute pain on opioid-related overdose deaths assessed via interrupted time series analyses. International Society for Pharmacoeconomics Outcomes Research 2021 Annual Meeting. Virtual.
Published in: *Value in Health*. 2021;24:S133.
22. Keshwani S*, Grande I*, Maguire M, Vouri SM, **Goodin AJ** and JM Hincapie-Castillo. The effects of Florida’s opioid restriction law for acute pain on the utilization of prescription NSAID medications. American Academy of Pain Medicine 27th Annual Meeting. Virtual. April 23-25, 2021.
Published in: *Pain Medicine*.
23. **Goodin AJ**, Hincapie-Castillo JM, Maguire M, Okpeku A*, Min J and AG Winterstein. Enhancing Prediction of All-Cause 30-Day Inpatient Psychiatric Facility Readmissions Using Electronic Health Record-Derived Data. Academy Health 2021 Annual Research Meeting. Poster. Washington, DC (virtual). June 14-17, 2021.
24. Shen Y*, [Opioid Policy Pharmacy Student Workgroup]*, Adkins LE, Hincapie-Castillo JM, Vouri SM and **AJ Goodin**. Chronic Opioid Therapy: A scoping literature review on evolving clinical and scientific definitions. [Poster] Addiction Health Services Research Annual Meeting.
Published in: *Addiction Science & Clinical Practice* 2020;15(Suppl 2):A113.
25. Shen Y*, Hincapie-Castillo JM, Vouri SM, Dewar MA, Sumfest JM and **AJ Goodin**. Prescription patterns of adjuvant medications following opioid supply restriction law in Florida: An interrupted time series analysis. [Poster] Addiction Health Services Research Annual Meeting. ****Top Rated Abstract Award****
Published in: *Addiction Science & Clinical Practice* 2020;15(Suppl 2):A12.
26. Smith KM, Chirino AB, Easey T, Hernandez C, Moorman-Li R, **Goodin AJ**, Vouri Sm and JM Hincapie-Castillo. Comparing the current status of state laws of opioid prescribing restrictions in the United States. [Poster] Addiction Health Services Research Annual Meeting.
Published in: *Addiction Science & Clinical Practice* 2020;15(Suppl 2):A91.

27. Valdes IL, Possinger MC, Hincapie-Castillo JM, **Goodin AJ**, Dewar MA, Sumfest JM and SM Vouri. Changes in opioid utilization by provider type following a days' supply restriction policy. [Poster] Addiction Health Services Research Annual Meeting.
Published in: *Addiction Science & Clinical Practice* 2020;15(Suppl 2):A90.
28. Jugl S, Okpeku A,* Costales B*, Morris E, Alipour-Harris G, Hincapie-Castillo J, Stetten N, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y*, Adkins LE and **A Goodin**. A mapping literature review of medical cannabis clinical outcomes and quality of evidence in approved conditions in the United States from 2016 through 2019. [Poster] The Research Society on Marijuana Virtual Meeting. 2020.
Published in: *Cannabis* 2021;4(1):15-16.
29. Pham P, Albogami Y, Cicali B, Squires P, Sarayani A, Reams V, Rhew K, **Goodin A**, Schmidt S, Winterstein A and J Brown. Risk of thromboembolic events associates with concomitant use of hormonal contraceptives and selective serotonin reuptake inhibitors. [Podium] International Conference on Pharmacoepidemiology and Therapeutic risk management (ICPE) All Access (virtual meeting).
Published in: *Pharmacoepidemiology and Drug Safety* 2020;29(S3):613.
30. Costales B*, Brown JD, Henriksen C and **AJ Goodin**. Off-label gabapentin utilization for psychiatric indications using the Food and Drug Administration adverse event reporting system database from 1993-2019. [Poster] International Conference on Pharmacoepidemiology and Therapeutic risk management (ICPE) All Access (virtual meeting).
Published in: *Pharmacoepidemiology and Drug Safety* 2020;29(S3):271.
31. Jugl S, **Goodin AJ**, Henriksen C, Winterstein A and J Brown. Discontinuation and switching rates among women of childbearing age taking oral hormonal contraceptives: a retrospective cohort study in the United States. [Poster] International Conference on Pharmacoepidemiology and Therapeutic risk management (ICPE) All Access (virtual meeting).
Published in: *Pharmacoepidemiology and Drug Safety* 2020;29(S3):269.
32. Morris E, Costales B*, Jiang X, **Goodin A** and SM Vouri. Evaluation of a potential gabapentinoid- somnolence-stimulant prescribing cascade among adults: a prescription sequence symmetry analysis. International Conference on Pharmacoepidemiology and Therapeutic risk management (ICPE) All Access (virtual meeting). 2020.
Published in: *Pharmacoepidemiology and Drug Safety* 2020;29(S3):483.
33. Wang X, Zimmermann E, Brown J, **Goodin AJ** and A Winterstein. Risk of preterm and small for gestational age among women with inflammatory bowel disease using TNF alpha inhibitors during pregnancy. [Podium] International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) All Access (virtual meeting). 2020.
Published in: *Pharmacoepidemiology and Drug Safety* 2020;29(S3):23.
34. **Goodin AJ**, Hincapie-Castillo JM and SM Vouri. A pragmatic model for PharmD student engagement in social and administrative pharmacy research: University of Florida Opioid Research Workgroup. [Poster] The American Association of Colleges of Pharmacy (AACP) 2020 Annual Pharmacy Education Meeting. [Virtual due to COVID-19] ****Selected: Gallery Walk Highlighted Presentation by the Graduate Education Special Interest Group****
Published in: *American Journal of Pharmaceutical Education*. 2020;84(6).
35. Hincapie-Castillo JM, Unigwe IF, **Goodin AJ** and SM Vouri. Enhancing active learning of root cause analysis: An immersive medication error experience from multiple perspectives. [Poster] The American Association of Colleges of Pharmacy (AACP) 2020 Annual Pharmacy Education Meeting. [Virtual due to COVID-19]
Published in: *American Journal of Pharmaceutical Education*. 2020;84(6).
36. Jugl S, Keshwani S, Adkins L, Heldermon C, Winterstein A and **AJ Goodin**. A Systematic Review of Evidence for Cannabis and Cannabinoids as Adjuvant Therapy in Palliative and Supportive Oncology Care. [Poster] The 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. [Virtual presentation due to COVID-19]
Published in: *Journal of Clinical Oncology* 2020;38(15S):12091.
37. **Goodin AJ**, Huang JL, Park H, Hincapie-Castillo JM, Brown JD, Costales B*, Wilson D and WH Lo-Ciganic. Changes in Prevalence of High-Risk Opioid Use Quality Measures in Arizona, 2011-2018. [Poster] AcademyHealth Annual Research Meeting. 2020. [Virtual Presentation due to COVID-19]
38. Costales B*, Brown J and **AJ Goodin**. Outpatient off-label gabapentin utilization from 2011 to 2015 among United States adults. [Poster] International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 Annual Meeting. Virtual Presentation due to COVID-19.
Published in: *Value in Health* 2020;23:S137.
39. Hincapie-Castillo J, **Goodin AJ** and SM Vouri. Changes in Schedule II oral opioid volume dispensed in a private payer following Florida's acute pain opioid restriction law. [Poster] ISPOR 2020 Annual Meeting. Virtual presentation due to COVID-19.

- Published in:** *Value in Health* 2020;23:S135.
40. Desai R, Liu X, **Goodin AJ**, Gopal S, Mohandas R and H Park. Impact of changes in Medicare bundled payment policy and the FDA label for erythropoietin stimulating agents on anemia care, major adverse cardiovascular events, and mortality for patients undergoing hemodialysis. [Podium] ISPOR 2020 Annual Meeting. Accepted, but withdrawn due to COVID-19.
 41. LaPorte A, Roussos-Ross K, Vilanueva KM and **AJ Goodin**. Access and Barriers to Oral Health Care in Pregnancy. [Poster] The American College of Obstetricians and Gynecologists (ACOG) 2020 Annual Clinical and Scientific Meeting. Virtual presentation due to COVID-19.
Published in: *Obstetrics & Gynecology* 2020;135:30S. DOI: 10.1097/01.AOG.0000663252.62372.21
 42. Roussos-Ross D, Dukharan V and **AJ Goodin**. Is in utero marijuana exposure associated with childhood developmental delay? [Poster] The American College of Obstetricians and Gynecologists (ACOG) 2020 Annual Clinical and Scientific Meeting. Virtual presentation due to COVID-19.
Published in: *Obstetrics & Gynecology* 2020;135:181S. DOI: 10.1097/01.AOG.0000664476.72398.7c
 43. Shen Y*, Vouri SM, Hincapie-Castillo JM and **AJ Goodin**. Prescription Opioid Patterns Following Supply Restriction Policy among Patients Receiving Chronic Opioid Therapy: An Interrupted Time Series Analysis. The International Society for Pharmacoepidemiology (ISPE) 2020 Mid-Year Meeting. [Cancelled due to COVID-19]
Published in: *Pharmacoepidemiology and Drug Safety* 2020;29(S3):647.
 44. **Goodin AJ**, Brown JD, Hincapie-Castillo J, and D Roussos-Ross. Physician Perceptions of Opioid Supply and Monitoring Requirement Policy Changes. [Poster] The American Society of Addiction Medicine (ASAM) 51st Annual Conference. Virtual presentation due to COVID-19.
Published in: *Journal of Addiction Medicine* 2020;14(6):e382-e424.
 45. **Goodin AJ**, Huang JL, Park H, Hincapie-Castillo J, Brown JD, Costales B* and WH Lo-Ciganic. Change in Buprenorphine Prescriptions for Opioid Use Disorder Indications in Arizona from 2011-2016. [Podium] The 2019 Addictions Health Services Research (AHSR) Conference. Park City, Utah.
Published in: *Substance Abuse* 2019; 40(4):469-472 (Supp 77). DOI: <https://doi.org/10.1080/08897077.2019.1688221>
 46. Hincapie-Castillo J, **Goodin AJ**, Usmani SA, Possinger MC and SM Vouri. Changes in Opioid Utilization Following Florida's Acute Pain Restriction Policy. [Podium] The 2019 Addictions Health Services Research (AHSR) Conference. Park City, Utah.
Published in: *Substance Abuse* 2019; 40(4):469-472 (Supp 62).
 47. **Goodin AJ**, Huang JL, Park H, Hincapie-Castillo J, Brown JD, Costales B* and WH Lo-Ciganic. Trends in Controlled Substance Utilization in Arizona from 2011-2016, by Prescription Class. [Poster] The 2019 Addictions Health Services Research (AHSR) Conference. Park City, Utah.
Published in: *Substance Abuse* 2019; 40(4):469-472 (Supp 151).
 48. Usmani SA, Hollman J, Ourhaan N, Oueini R, Bhagwandass H, **Goodin AJ**, Hincapie-Castillo J and SM Vouri. Effects of Hydrocodone Rescheduling on Opioid Prescribing Outcomes: A Systematic Review. [Poster] The 2019 addictions Health Services Research (AHSR) Conference. Park City, Utah.
Published in: *Substance Abuse* 2019; 40(4):469-472 (Supp 187).
 49. Delcher C, Wang Y, **Goodin AJ**, Freeman PR, and G Reisfield. Rapid Expansion of the Opioid Ecosystem: National Implications for Prescriber-Pharmacist Communication. [Poster] Academy Health 36th Annual Research Meeting. *Health Workforce Session*. Washington, DC.
 50. **Goodin AJ**, Elswick A, and A Fallin-Bennett. Mental Health Disparities and High-Risk Alcohol Use Among Non-Heterosexual High School Students. [Poster] Academy Health 36th Annual Research Meeting. *Disparities and Health Equity Session*. Washington, DC.
 51. **Goodin AJ**, Squires P, Henriksen C, Jugl S, Winterstein A, and JD Brown. Prevalence of Prescription Contraceptives Following the Affordable Care Act Contraception Coverage Mandate in a Commercially Insured Population. [Poster] 2019 Academy Health 36th Annual Research Meeting. *Women's Health Session*. Washington, DC.
 52. **Goodin AJ**, Brown JD, Freeman TR, Henry SG, Talbert J and C Delcher. Obstetrician/Gynecologist Perception of Prescription Drug Monitoring Program Effectiveness. [Poster] The American College of Obstetricians and Gynecologists (ACOG) 2019 Annual Clinical and Scientific Meeting. Nashville, Tennessee.
Published in: *Obstetrics & Gynecology* 2019; 133: 99S. DOI: 10.1097/01.AOG.0000558792.87713.72
 53. Roberson D, **Goodin AJ** and D Roussos-Ross. (2018). Impact of On-Site Perinatal Mood Disorders Clinic in the Diagnosis and Management of Perinatal Mood Disorders. [Poster] The American College of Obstetricians and Gynecologists (ACOG) 2019 Annual Clinical and Scientific Meeting. Nashville, Tennessee.
Published in: *Obstetrics & Gynecology* 2019; 133: 14S. DOI: 10.1097/01.AOG.0000559362.65334.2a

54. Padilla M, **Goodin AJ**, and D Roussos-Ross. Is there a correlation between elevated Healthy Start Screen Scores and development of postpartum Depression? [Poster] The American College of Obstetricians and Gynecologists (ACOG) 2019 Annual Clinical and Scientific Meeting. Nashville, Tennessee.
Published in: *Obstetrics & Gynecology* 2019; 133: 137S.
DOI: 10.1097/01.AOG/01.AOG.0000559266.40266.3a
55. Roussos-Ross D, Delcher C, Brown JD, Bae J, and **AJ Goodin**. Perceptions and Utilization of Prescription Drug Monitoring Programs: A survey of ACOG Members. [Poster] The American College of Obstetricians and Gynecologists (ACOG) 2019 Annual Clinical and Scientific Meeting. Nashville, Tennessee.
Published in: *Obstetrics & Gynecology* 2019; 133: 181S. DOI: 10.1097/01.AOG.0000558925.95749.f1
56. Fallin-Bennett A, Rademacher K, Dye H, Elswick A, Ashford K and **A Goodin**. A Navigator Approach to Reduce Tobacco Use among Pregnant and Postpartum Women with Highly Prevalent Opioid Use Disorder. [Poster] The Society for Research on Nicotine & Tobacco 25th Annual Meeting. San Francisco, California.
57. **Goodin AJ**, Talbert J, Freeman PR, Hahn E and A Fallin-Bennett. (2018). *Tobacco Cessation Treatment Utilization by Kentucky Medicaid Recipients Before and After Medicaid Expansion and Mandated Tobacco Treatment Coverage: 2013-2015*. [Poster] The 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Prague, Czech Republic.
Published in: *Pharmacoepidemiology and Drug Safety* 2018;27(S2): 507. DOI: 10.1002/pds.4629
58. Roussos-Ross D, Prieto A, Watson A and **AJ Goodin**. (2018). *Are 'CenteringPregnancy' Patients More Likely Than Traditional Care Patients to Select LARC?* [Poster] American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Austin, Texas.
Published in: *Obstetrics & Gynecology* 2018;131: 63S. DOI: 10.1097/AOG.0000000000002569
59. Prieto A, **Goodin AJ**, Watson A and D Roussos-Ross. (2018). *Are 'CenteringPregnancy' Patients More Likely Than Traditional Care Patients to Receive Influenza Vaccination?* [Poster] American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Austin, Texas.
Published in: *Obstetrics & Gynecology* 2018;131: 34S. DOI: 10.1097/01.AOG.0000532957.31654.f4
60. Watson A, **Goodin AJ**, Prieto A and D Roussos-Ross. (2018). *Is Participation in 'CenteringPregnancy' Associated with Decreased Postpartum Depression in Black Women?* [Poster] American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Austin, Texas.
Published in: *Obstetrics & Gynecology* 2018;131: 46S. DOI: 10.1097/01.AOG.0000533000.90857.38
61. Raissi D, **Goodin AJ**, Han Q and JD Brown. (2018). *Inferior Vena Cava Filter Retrieval Initiatives: A 2008-2017 Systematic Review*. [Poster] International Symposium on Endovascular Therapy Annual Meeting. Hollywood, Florida.
62. Sachdeva A, Hall CP, **Goodin AJ**, Nasser M, Rogers A and DC Preston. (2017). *The Neuropharmacology of Epilepsy: An Interprofessional Educational Initiative for Neurology Residents*. [Poster] American Epilepsy Society Annual Meeting. Washington, D.C.
63. Fallin-Bennett A, Scott T, Fallin-Bennett K and **AJ Goodin**. (2017). *Substance Abuse and School Characteristics in LGB and Heterosexual High School Students*. [Poster] American Public Health Association Annual Meeting. Atlanta, Georgia.
64. **Goodin AJ**, Talbert J, and J Brown. (2017). *Rural and Appalachian Disparities in Neonatal Abstinence Syndrome and Access to Opioid Abuse Treatment*. [Poster and Pediatrics Spotlight Presentation] International Society for Pharmacoepidemiology Annual Meeting. Montreal, Quebec, Canada. ****Winner: Best Spotlight Poster****
Published in: *Pharmacoepidemiology & Drug Safety* 2017;26(S2): 271.
65. Stoner SC, Cutler A, Cunningham P, Vanderhoef D, Fowler JB and **AJ Goodin**. (2017). *Assessment of Learning from an Interprofessionally Delivered CE Activity on Tardive Dyskinesia for Psychiatric Specialty Nurses*. [Poster] The College of Psychiatric and Neurologic Pharmacists Annual Meeting. Phoenix, Arizona.
66. Moga D, Wu Q, Doshi P and **AJ Goodin**. (2016). *Sex Differences in Factors Predicting the Type of Bladder Antimuscarinics Initiated in Medicare Nursing Home Residents*. [Poster] International Society for Pharmacoepidemiology Annual Meeting. Dublin, Ireland.
Published in: *Pharmacoepidemiology & Drug Safety* 2016;25(S3): 654.
67. Collard C, **Goodin AJ**, Matson A and A Policastri. (2016). *Assessment of Pharmacist Knowledge Change by Practice Site Following Completion of an Online Continuing Pharmacy Educational Diabetes Management Activity*. [Poster] American Society of Health-Systems Pharmacists Annual Midyear Clinical Meeting and Exhibition. Las Vegas, Nevada.

68. **Goodin AJ**, Green TC, Fallin A, Troske S and PR Freeman. (2016). *A Survey Study of Kentucky Pharmacists' Willingness to Participate in Needle Exchange*. [Poster] American Pharmacists Association Annual Meeting. Baltimore, Maryland.
Published in: *JAPhA* 2016;56(3): e105. DOI: 10.1016/j.japh.2016.03.014
69. Freeman PR, **Goodin AJ**, Fallin A, Troske S and TC Green. (2016). *Pharmacists' Role in Opioid Overdose Prevention: A Survey Study of Kentucky Pharmacists' Willingness to Participate in Naloxone Dispensing*. [Poster] American Pharmacists Association Annual Meeting. Baltimore, Maryland.
Published in: *JAPhA* 2016;56(3): e106. DOI: 10.1016/j.japh.2016.03.014
70. Freeman PR, Troske S, **Goodin AJ** and J Talbert. (2016). *Impact of Mandatory Query Legislation on Patient Doctor-Shopping Behavior*. [Poster] American Pharmacists Association Annual Meeting. Baltimore, Maryland.
Published in: *JAPhA* 2016;56(3): e59. DOI: 10.1016/j.japh.2016.03.014
71. Noel ZR, Matson A, **Goodin A** and TE Macaulay. (2016). *Relationship between Faculty Evaluation Scores on Participant Knowledge Retention Rates in Continuing Pharmacy Education Activities*. [Poster] American Cardiology Conference Annual Meeting. Chicago, IL.
72. Matson A, **Goodin AJ**, Shotyk L and B Jack. (2016). *Exploring Targeted Interprofessional Strategies to Create Connections Across the Continuum of Care*. [Poster] Alliance for Continuing Education in the Health Professions Annual Meeting. National Harbor, Maryland.
73. **Goodin AJ** and A Fallin. (2015). *Impact of Naloxone Access Policies on Opioid Overdose Deaths*. [Podium Presentation] American Public Health Association Annual Meeting. Chicago, Illinois.
74. Troske S, Freeman PR, **Goodin AJ**, Blumenschein K and J Talbert. (2015). *The Relationship between Pseudoephedrine Sales and Clandestine Methamphetamine Labs*. [Poster] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. Philadelphia, Pennsylvania.
Published in: *Value in Health* 2015;18(3): A125. DOI: 10/1016/j.val.2015.03.728
75. Freeman PR, Troske S, **Goodin AJ**, Blumenschein K and J Talbert. (2015). *Impact of Kentucky House Bill 1 on Concurrent Prescribing of Opioid, Alprazolam, and Carisoprodol*. [Poster] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. Philadelphia, Pennsylvania.
Published in: *Value in Health* 2015;18(3): A128. DOI: 10/1016/j.val.2015.03.748
76. Lee YO, **Goodin AJ**, and A Fallin. (2014). *Current tobacco product use among sexual minorities in the United States: Smokeless tobacco, Snus, cigar, hookah and pipe*. [Podium Presentation] American Public Health Association Annual Meeting. New Orleans, Louisiana.
77. Bennett K, **Goodin AJ**, Fallin A and YO Lee. (2014). *Awareness of Smoking Cessation Methods among LGBT and heterosexual individuals*. [Poster] American Public Health Association Annual Meeting. New Orleans, Louisiana.
78. Fallin A, **Goodin AJ**, and B King. (2014). *Menthol Cigarette Smoking among Lesbian, Gay, Bisexual, and Transgender Adults in the United States*. [Podium Presentation] American Public Health Association Annual Meeting. New Orleans, Louisiana.
79. Fallin A, **Goodin AJ**, Lee YO, and K Bennett. (2014). *Lesbian, Gay, and Bisexual Orientations as Contexts for Tobacco-Related Health Disparities*. [Refereed Roundtable Presentation] American Sociological Association Annual Meeting. San Francisco, California.
80. **Goodin AJ**, S Kiteck and MA Williamson. (2014). *Patient-Reported Quality of Life and Satisfaction with Services among Money Follows the Person Participants*. [Poster] Academy Health Annual Research Meeting. San Diego, California.
81. **Goodin, AJ**. (2014). *The Relationship between State Prescription Drug Monitoring Program Characteristics and Controlled Substance Dispensing to Medicaid Beneficiaries*. [Poster] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. Montreal, Quebec, Canada.
Published in: *Value in Health* 2014;17(3): A221-A222. DOI: 10.1016/j.val.2014.03.1296
82. Wixson S, Blumenschein K, **Goodin AJ**, Talbert J, and PR Freeman. (2014) *Community Pharmacist Characteristics Associated with Use of A Prescription Drug Monitoring Program*. [Poster] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. Montreal, Quebec, Canada.
****Winner: Best Poster****
Published in: *Value in Health* 2014;17(3): A15. DOI: 10.1016/j.val.2014.03.096
83. **Goodin AJ**, Perin N, Freeman PR, Talbert J, Wittmer D, and K Blumenschein. (2013). *The Association between Burn Injuries and Pseudoephedrine Sales*. [Podium Presentation] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. New Orleans, Louisiana. *****Winner: Best Podium Presentation*****
Published in: *Value in Health* 2013;16(3): A9. DOI: 10.1016/j.val.2013.03.057

84. **Goodin AJ**, Freeman PR, Talbert J, Monson K, and K Blumenschein. (2013). *Kentucky Physician Opinions of the Potential Reclassification of Pseudoephedrine as a Legend Drug*. [Poster] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. New Orleans, Louisiana.
Published in: *Value in Health* 2013;16(3): A249. DOI: 10.1016/j.val.2013.03.1271
85. Monson K, Freeman PR, **Goodin AJ**, Talbert J, and K Blumenschein. (2012). *Kentucky Pharmacist Opinions of the Potential Reclassification of Pseudoephedrine as a Legend Drug*. [Poster] American Society of Health System Pharmacists Midyear Meeting. Las Vegas, Nevada.
86. **Goodin AJ** and Fallin, A. (2012). *The Association Between Emergency Department Utilization by Kentucky Medicaid Patients and Smoke-Free Ordinances*. [Poster] American Public Health Association Annual Meeting. San Francisco, CA.
87. **Goodin AJ**, Blumenschein K, Freeman PR, and J Talbert. (2011). *Prescription Drug Monitoring Programs: The Patient Perspective*. [Poster] International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. Baltimore, Maryland.
Published in: *Value in Health* 2011;14(3): A15.
88. **Goodin AJ**. (2010). *Switching Statins in a Medicaid Population: The Health Outcomes and Policy Implications of Formulary Restrictions*. [Poster] Academy Health Annual Research Meeting. Boston, Massachusetts.
89. **Goodin AJ** and D Nau. (2008). *Racial Differences in Patients' Adherence to Diabetes Medications*. [Podium Presentation] American Pharmacists Association Annual Meeting. San Diego, California.
Published in: *Journal of the American Pharmacists Association* 2008;48(2): 283.

Regional and Local Presentations, selected

1. Roberson D, **Goodin A**, Thompson L and D Roussos-Ross. (2018). *Pregnancy-Related Characteristics of Women Cared for within a Perinatal Mood Disorder Clinic: A Pilot Study*. [Poster] 5th Annual Pediatric Research Forum for Medical Students. Orlando, Florida.
2. Halloran D, O'Connor S, **Goodin A**, and S Byun. (2018). *Contraception Options Counseling Assessment for Bias from Healthcare Workers on Community Patients*. [Poster] Society for Student-Run Free Clinics Annual Meeting. Omaha, Nebraska.
3. O'Connor S, Halloran D, **Goodin A**, and S Byun. (2018). *Community Women and Contraception: A Health Needs Assessment in the Spirit of Reproductive Autonomy*. [Podium Presentation] University of Florida Social Justice Summit. Gainesville, Florida.
4. **Goodin AJ** and TR Freeman. (2015). *Role of pharmacists in preventing opioid overdose: Perceptions of Kentucky Pharmacists*. [Podium Presentation]. Advances in Pharmacy Practice: Annual Fall Conference. Lexington, Kentucky.
5. Fowler JB, Matson A, and **AJ Goodin**. (2015). *Opportunities to Improve Clinical Touch Points with Targeted Interprofessional Continuing Education*. [Poster] 1st Annual Southeastern Interprofessional Education Conference. Pigeon Forge, Tennessee.
6. **Goodin, AJ**. (2013). *Three Participatory Learning Activities to Introduce Public Policy Concepts in the Economic Principles Course*. [Podium Presentation] Panel Title: Innovative Ideas for Teaching Economics. Kentucky Economic Association Conference. Frankfort, Kentucky.
7. **Goodin AJ**, Perin N, Freeman PR, Talbert J, Wittmer D, and K Blumenschein. (2013). *The Association between Burn Injuries and Pseudoephedrine Sales*. [Podium Presentation]. The Center for Clinical and Translational Sciences Annual Spring Conference. Lexington, Kentucky.
8. **Goodin AJ**. (2009). *The Implementation of Kentucky Transitions: A Money Follows the Person Demonstration Grant Program*. [Podium Presentation] Southeastern Conference on Public Administration. Louisville, Kentucky.
9. **Goodin AJ**. (2009). *The Financial and Economic Impacts of Kentucky's High Tobacco Use*. [Podium Presentation] Institute for Rural Journalism and Community Issues, workshop for Kentucky Journalists. Madisonville, Kentucky.

Graduate Student Supervision

<u>Dates</u>	<u>Student</u>	<u>Degree, Program</u>	<u>Role</u>	<u>Status</u>	<u>First Position</u>
2023-Present	Kimia Zandbiglari	PhD, POP	Member	In progress	---
2023-Present	Jabed Al Faysal	PhD, POP	Member	In progress	---
2022-Present	Yanning Wang	PhD, POP	Member	In progress	---
2022-Present	Celeste Ewig	PhD, POP	Member	In progress	---
2022-Present	Sumaya Abuloha	PhD, POP	Member	In progress	---
2022-2023	Golnoosh Alipour-Haris	PhD, POP	co-Chair	Completed	Senior Scientist, CORE Department, Merck
2022-Present	Hsin-Min (Grace) Wang	PhD, POP	Member	In progress	---
2022-Present	Sebastian Jugl	PhD, POP	Member	In progress	---
2022-2023	Rupal Aroza	MS, POP	Member	Completed	PhD program, University of Kentucky
2021-2023	Ikenna Unigwe	PhD, POP	Member	Completed	Associate Director, Global Epidemiology, Boehringer Ingelheim
2021-Present	Shu Huang	PhD, POP	Member	In progress	---
2021-2023	Boya Lin	PhD, Health Outcomes and Bioinformatics	Member	Completed	Pharmacoepidemiologist, Analysis Group
2021-2022	Hayley Markovich	PhD, Science and Health Communication	Member	Completed	---
2021-2021	Shailina Keshwani	MS, POP	Member	Completed	PhD program, University of Florida
2020-2023	Phuong (Phoenix) Tran	PhD, POP	Member	Completed	Associate Director in RWE & Analytics, Boehringer-Ingelheim
2020-2021	Aram Babcock	PhD, POP	Member	Completed	Post-Doctoral Fellow, Janssen Pharmaceutical Companies of J&J
2019-2022	Brianna Costales	PhD, POP	Chair	Completed	Post-Doctoral Fellow, Kaiser Permanente
2019-2021	Aimalohi Okpeku	MS, POP	Chair	Completed	PhD Program, Virginia Commonwealth University
2019-2020	Xi Wang	PhD, POP	Member	Completed	Epidemiologist, FDA

NIH Study Section Grant Reviewing Service

NIH NIDA SBIR Special Emphasis Panel. Ad-Hoc study section member. November 30, 2022.

NIH Early Career Researcher (ECR) Reviewer Program: Organization and Delivery of Health Services (ODHS) Study Section. June 23-24, 2022.

University of Florida College of Pharmacy and POP Department Service

POP Department Faculty Search Committee: Open Rank position. Service from January 2024-Present.

College of Pharmacy Faculty Governance Council. POP Department Representative. September 2023-Present.

College of Pharmacy PROSPER Faculty Development Committee. Ad Hoc Intramural Funding Application Reviewer. June 2023.

Center for Drug Evaluation and Safety (CoDES) Advisory Committee member from February 2023-Present. Faculty lead of Maternal and Child Health Research Core from 2021-February 2023.

College of Pharmacy Research Faculty Search Committee. Service from March 2022-August 2022.

POP Department Faculty Search Committee: Clinical Assistant Professor position. Service from January 2022-June 2022.

POP Department Faculty Search Committee: Pharmacoeconomics Open Rank position. Service from July 2021-August 2022.

POP Department Faculty Search Committee: PHSR Open Rank position. Service from July 2021-August 2022.

College of Pharmacy Mentoring Academy Faculty Development Lead, with Kalen Manasco and Brandon Warren. Service from April 2021-2023.

Committee and Task Force Member: Evaluating methods to improve PharmD education on the BIPOC (Black, Indigenous, and People of Color) experience and health inequities. Service from July 2020-December 2021.

Journal Editorial Boards and Leadership Roles

2023-Present	<i>Medical Cannabis & Cannabinoids</i> , Associate Editor
2021-Present	<i>Pain Medicine</i> , Co-Morbid Pain & Substance Use Disorders Section, Board Member
2020-2023	<i>Medical Cannabis & Cannabinoids</i> , Board Member
2019-2021	<i>Pain Medicine</i> , Opioids & Substance Use Disorders Section, Board Member

Journals: Ad-Hoc Peer Review

Regular service for the following journals, see link for service history and dates: JAMA Health Forum, American Journal of Psychiatry, Journal of Addiction Medicine, Women's Health Issues, Substance Use, Pain Medicine, Journal of Pediatrics, Medical Care, BMJ Open, American Journal of Public Health, Journal of Rural Health, Health Services Research, Substance Use and Misuse, Journal of the American Pharmacists Association.

[Verified Reviewer Service History](#)

Service: Mentoring, Professional Organizations, Community

<u>Date</u>	<u>Service Activity: Mentoring</u>
2023-Present	College of Pharmacy Honors Research, service as faculty mentor. Mentee: Dionna Shine.
2023-Present	Faculty Mentoring Committee Member: Rachel Reise.
2023-Present	International Pharmacy Resident Research Experience, supervised research project for each of the following mentees: Nele Melcher, Laura Springer, Lena Froehlich, Thorben Korzbach, Peggy Poelzing, Diana Kretschmer.
2022-2023	College of Pharmacy Research Project, service as faculty mentor. Mentee: Jerry Staret. First placement: Fellowship in Late Stage Clinical Development Oncology, Merck (May 2023).
2022-2023	College of Pharmacy Honors Research, service as faculty mentor. Mentee: Russell Ryan.
2022	Supervised Teaching, 3-hour course credit. Mentee: Sebastian Jugl.
2021-2022	College of Pharmacy Research Project, service as faculty mentor. Mentee: Tychell Branchcomb. First placement: Rutgers Institute for Pharmaceutical Fellowship (RPIF).
2021-2022	College of Pharmacy Honors Research, service as faculty mentor. Mentee: Nhi Tran.
2021	College of Pharmacy Research Project, service as faculty mentor. Mentees: Maryam Deravi, Ashmita Jadubans.
2021-2022	College of Pharmacy Research Elective, service as faculty mentor. Mentees: Kayla Smith, Aolani Chirino, Mikela Mollanazar.

2021-2022	College of Pharmacy Research Elective, service as faculty mentor. Mentee: Rachel Matthews.
2020-2021	College of Pharmacy Honors Research, services as faculty mentor. Mentee: Kristen Martinez.
2019-Present	College of Pharmacy Opioid Policy Research Workgroup, service as faculty mentor (multiple PharmD students).
2019-2020	College of Pharmacy Honors Research, service as faculty mentor. Mentee: Victoria Reams.
2019	Summer Undergraduate Research at Florida (SURF), service as faculty mentor. Mentee: Shirley Sanchez.
2018-2019	University of Florida Multicultural Mentor Program, service as faculty mentor. Mentee: Christina Chau.
2013	Microteaching Mentor, provided ~20 hours of classroom instruction training for University of Kentucky TAs and new instructors: Lexington, KY.
2013	Professional student mentor volunteer for Center for Clinical and Translational Science Spring Conference: Lexington, KY.

<u>Year(s)</u>	<u>Service Activity: Review, Conference Abstracts</u>
2021-2023	Cannabis Clinical Outcomes Research Conference (CCORC) annual meeting.
2021-2023	Academy Health Annual Research Meeting conference abstracts.
2018-2023	International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE)
2016, 2019	American Public Health Association 2016 and 2019 Annual Meeting and Expo
2015	International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2015	Society of Medical Decision Making's 37 th Annual Meeting

<u>Date</u>	<u>Service Activity: Guest Lectures and Service to K-12 Public Schools</u>
2022, 2023	Invited Guest Speaker for Pharmacy and Pharmacy Research Careers, for Florida high school students, UF Pharmacy Summer Camp.
2022	Guest Speaker, Invited Local Talk for APhA-ASP "Operation Substance Use Disorders" at University of Florida College of Pharmacy: Gainesville, FL.
2021	Academy Health's "Health Research Exchange" featured paper and visual abstract.
2020	Guest Speaker, Invited Local Talk for APhA-APA "Generation Rx- Substance Use Disorders series" at University of Florida College of Pharmacy: Gainesville, FL.
2020	Guest Speaker, Alachua County Senior Recreation Center ("What to know about medical marijuana and CBD"); Gainesville, FL.
2020	Guest Lecturer (titled "An Introduction to Health Policy for Pharmacy") for University of Kentucky College of Pharmacy course on Public Health: Lexington, KY.
2020	Poster judge, UF COP Research Showcase: Gainesville, FL.
2015	Guest Lecturer (titled "An Introduction to Health Insurance and Public Policy") for the Martin School of Public Policy's graduate course on Public Policy Economics: Lexington, KY.
2014	Methods Workshop Instructor (titled "Secondary Data Analysis") for the POP Summer Research Immersion Program: Lexington, KY.
2013	Statistics Workshop Instructor (titled "Working with Stata") for POP Summer Research Immersion Program: Lexington, KY.
2013	Poster judge for Center for Clinical and Translational Science Spring Conference: Lexington, KY.

<u>Date</u>	<u>Service Activity: Professional Associations and Committees</u>
2023-Present	Academy Health State Health Interest Group Advisory Council. Member-at-Large. Nominated/elected for 2-year term beginning in September 2023.
2023-Present	ISPE Mid-Year Scientific Program Co-Chair. ICPE Mid-Year meeting in Orlando, Florida.
2022-Present	co-Chair, Scientific Program Committee, Cannabis Clinical Outcomes Research Conference.
2023	Chair and Discussant, Panel Session “Opioid Prescribing and OUD Treatment in the United States,” Academy Health Annual Research Meeting.
2022-Present	ISPE Workgroup on Developing Pharmacoepidemiology Core Competencies.
2021-2022	Chair, Academic Council in International Society for Pharmacoepidemiology (ISPE).
2021-Present	Member, Opioid Data Lab research collaborative
2021	Chair and Discussant, Panel Session “Marketplace Insurance Coverage: Key Issues and Comparisons with Medicaid,” Academy Health Annual Research Meeting.
2020-2021	CCORC Conference Program Chair, Consortium for Medical Marijuana Clinical Outcomes Research.
2020-2022	Chair, Scientific Program Committee, Consortium for Medical Marijuana Clinical Outcomes Research Annual Conference.
2020-2021	Co-Chair, Academic Council in International Society for Pharmacoepidemiology (ISPE).
2018-Present	State Health Research and Policy Interest Group in Academy Health.
2018-Present	Disparities Interest Group in Academy Health.
2018-2021	Educational Affiliate: American College of Obstetricians and Gynecologists (ACOG).
2018-Present	Drug Utilization/Health Service Research Special Interest Group (SIG) in ISPE.
2017-Present	Member, International Society for Pharmacoepidemiology (ISPE).
2013	Member, Society of Medical Decision Making (SMDM).
2012-2015	Member, Association for Public Policy Analysis and Management (APPAM).
2011-2016	Member, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2008-Present	Member, Academy Health.

AWARDS & HONORS

<u>Date</u>	<u>Award or Honor</u>
2023	University of Florida College of Pharmacy 2022-2023 Teaching and Service Award.
2022	Center for Public Health Law Fellow. 2-Year fellowship term, selected March 4, 2022.
2021	“Exceptional Reviewer” recognition for 2020-2021 service to <i>Journal of Rural Health</i> .
2021	“Outstanding Reviewer” recognition awarded by the <i>Journal of the American Pharmacists Association</i> .
2020	“Exceptional Reviewer” recognition for 2019-2020 service to <i>Journal of Rural Health</i> .
2020	“Outstanding Contribution in Reviewing” recognition awarded by <i>Journal of the American Pharmacists Association</i> .
2020	University of Florida Open Access Publishing Fund grant: \$1,500.
2019	“Exceptional Reviewer” recognition for 2018-2019 peer review service to <i>Journal of Rural Health</i> .
2019	HCUP Outstanding Article of the Year Award- Honorable Mention, conferred by AHRQ and AcademyHealth, for “Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment” published in <i>Journal of Rural Health</i> .
2019	PROSPER Faculty Development funding for University of Florida College of Pharmacy- funded to attend mentoring training conference: \$375.
2018	“Exceptional Reviewer” recognition for 2017-2018 for service to <i>Journal of Rural Health</i> .
2018	“Outstanding Contribution in Reviewing” recognition for service to <i>Journal of Pediatrics</i> .
2018	University of Florida Open Access Publishing Fund grant: \$1,550.
2017	Best Spotlight Poster: Pediatrics Special Interest Group, International Conference on Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting.
2017	University of Florida Open Access Publishing Fund grant: \$1,500.

2014	Best Poster Award, International Society of Pharmacoeconomics and Outcomes Research Annual Meeting.
2014	University of Kentucky Graduate School Travel and Research Funding grant: \$800.
2014	Thomas D. Clark Medallion awarded to <i>Kentucky Government, Politics, and Public Policy</i> , by Thomas D. Clark Foundation.
2013	Best Student Podium Presentation Award, International Society of Pharmacoeconomics and Outcomes Research Annual Meeting.
2013	University of Kentucky Graduate School Travel and Research Funding grant: \$400.
2013	Second Place Poster Award: Rho Chi Society Research Day, UK College of Pharmacy.

SUPPLEMENTAL TRAINING in RESEARCH & LEADERSHIP & MENTORING

<u>Training Year; Duration</u>	<u>Course Title; Training Provider; Location</u>
2021; 4.5 Hours	University of Florida Certificate in Multicultural Mentoring. Sessions: 'Bridging differences for better mentoring,' 'Why mentoring matters for diversity, equity and inclusion: moving from research to practice,' 'Equity-based mentorship and supporting early career scholars of color.' Gainesville, FL.
2021; 5 Hours	Train the Trainers ("Mentor-the-Mentor Workshop"): Mentoring Graduate Students. University of Florida Clinical Translational Sciences Institute (CTSI), Mentor Academy; Gainesville, FL.
2020; 1 Hour	Diversity and Inclusion: Building Connection and Community in Physical, Online, and Hybrid Classrooms; Harvard Business Publishing Education; Virtual Webinar.
2019; 4 Hours	Modern Pregnancy and Pharmacoeconomics: Selected Analytic Considerations in the Study of Drug Safety in Pregnancy; ICPE 35 th Annual Meeting; Philadelphia, PA.
2019; 8 Hours	International Mentoring Association 30 th Annual Conference (mentoring training); Gainesville, FL.
2018; 4 Hours	Advanced Drug Utilization Research; ICPE 34 th Annual Meeting; Prague, Czech Republic.
2013; 80 Hours	"SuperVision" Management Training for Personnel Supervisors; University of Kentucky; Lexington, KY.
2012; 4 Hours	Content Validity of Patient Reported Outcomes, Clinician Reported Outcomes, and Observer Reported Outcomes Assessments; ISPOR 17 th Annual Meeting; Washington, DC.
2012; 4 Hours	Introduction to Design & Analysis of Comparative Effectiveness Studies Using Retrospective Databases; ISPOR 16 th Annual Meeting; Baltimore, MD.
2012; 4 Hours	Advanced Patient Reported Outcomes Assessment- Psychometric Methods; ISPOR 16 th Annual Meeting; Baltimore, MD.
2011-2012; 3 Courses	Coursework to develop competencies with: REDCap, SQL, PERL, ArcGIS mapping software, HTML, and Stata; Public Health + Bioinformatics; University of Kentucky; Lexington, KY.
2011; 40 Hours	Teaching Methods in Economics; Gatton College of Business and Economics, University of Kentucky; Lexington, KY.

RESEARCH PRESS COVERAGE and REAL-WORLD IMPACT

Federal Scientists Recommend Easing Restrictions on Marijuana. Christina Jewett and Noah Weiland. *New York Times*. January 12, 2024. [Study coverage](#).

Department of Health and Human Services (HHS). Letter and Accompanying Report to the Drug Enforcement Administration (DEA), titled, "Basis for the recommendation to reschedule marijuana into Schedule III of the Controlled Substances Act." Report released on January 12, 2024. [Studies cited in HHS Federal Regulation Recommendation in addition to contributor](#).

Raise the age of majority- and not just for buying guns. Jason Willick. *Washington Post*. June 2, 2022. [Study coverage](#).

United States Food and Drug Administration. Regulatory Action: 21 CFR Part 1166. May 4, 2022. [Study cited in United States Federal Register.](#)

Many Psychiatric Patients are Getting Risky Drug Gabapentin ‘Off-Label’. Amy Norton. November 22, 2021. *US News & World Report*. [Study coverage and quoted within interview.](#)

Florida’s Restrictive Opioid Law Did Not Lead to Increased NSAID Prescriptions. Jessica Nye. July 27, 2021. *Clinical Pain Advisor*. [Study coverage.](#)

Off-Label Psychiatric Use of Gabapentin Found to be Frequent, Risky. May 24, 2021. *Psychiatric News*. [Study coverage.](#)

Smoking Cessation: A Report of the Surgeon General. United States Department of Health and Human Services. 2020. [Study cited in Report.](#)

Florida Law Tightened Opioid Prescribing, and Saw Usage Drop. Robert Preidt, March 3, 2020. *Health Day (Medicine Net)*. [Study coverage.](#)

Florida Law Limiting First Opioid Prescription Linked to Drop in Use. Linda Carroll, February 28, 2020. *Reuters and The New York Times*. [Study coverage.](#)

White House Touts Progress in Opioid Crisis, but Health Researchers are Skeptical. Emma Newburger, March 26, 2019. *CNBC*. [Quoted within Interview.](#)

Reducing Opioid Prescriptions Saves Lives but Also Leads to More Heroin Use and Deaths. Partnership News Service Staff. March 6, 2019. *Partnership for Drug-Free Kids & Center on Addiction*. [Quoted within.](#)

The Opioid Dilemma: Saving Lives in the Long Run Can Take Lives in the Short Run. Austin Frakt, March 4, 2019. *The New York Times*. [Quoted within Interview.](#)

Role of Pharmacists in Harm Reduction: Syringe/Needle Exchange. Jeanette Y. Wick, June 13, 2018. *Pharmacy Times*. [Study coverage.](#)